Growth after pediatric heart transplantation

Broux, Eric De; Huot, Céline; Chartrand, S; Chartrand, C

doi:10.1016/s0041-1345(00)02662-2

Cited by 9 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were reported by De Broux et al. in 25 patients transplanted at a median of 13 yr (11 months–17 yr) (27). At the time of transplantation, 24% were growth delayed (height and weight <5th percentile).…”

Section: Discussionsupporting

confidence: 89%

Anthropometric growth and utilization of enteral feeding support in pediatric heart transplant recipients

Bannister

Manlhiot

Pollock-BarZiv

et al. 2010

Pediatric Transplantation

View full text Add to dashboard Cite

We sought to outline trends in anthropometric growth before and after cardiac transplantation and to document our experience with the use of EFS in this population. A total of 130 patients (59% male) were enrolled and followed for a median of 4.4 yr after transplantation. Negative changes over time in weight z-score (EST: -0.256 [0.160] z/yr, p = 0.01), height z-score (EST: -0.214 [0.096] z/yr, p = 0.03), and BMI z-score (EST: -0.287 [0.161] z/yr, p = 0.07) were observed prior to transplantation. Significant increases in weight z-score (EST: +0.342 [0.143] z/yr, p < 0.001) and BMI z-score (EST: +0.396 [0.140] z/yr, p = 0.005) were seen in the first 18 months following transplantation. No further increases in height, weight, or BMI z-score were seen beyond this. Forty-two (32%) patients received EFS. Prior to transplantation, it was not found to be associated with change in anthropomorphic growth. Post-transplantation exposure to EFS was associated with a faster increase in weight z-score (EST: +0.480 [0.231] z/yr, p = 0.04) and height z-score over time (EST: +0.366 [0.141] z/yr, p = 0.01). Normalization of weight and height z-scores was not achieved during the study follow-up period. This study suggests that further investigation into the role of EFS is warranted to identify strategies to improve growth in pediatric heart transplant recipients.

show abstract

Section: Discussionsupporting

confidence: 89%

Anthropometric growth and utilization of enteral feeding support in pediatric heart transplant recipients

Bannister

Manlhiot

Pollock-BarZiv

et al. 2010

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…The incidence of PG in the pediatric heart failure population is also high with a reported range of 21–37% . Unlike the adult literature where pre‐transplant cachexia is a strong predictor of mortality, the pediatric literature has described varying effects .…”

Section: Discussionmentioning

confidence: 99%

“…There was, however, a trend toward worse five-yr survival in Fontan patients with HA (57.55% vs. 80.99%, p = 0.072) which may have reached significance with a larger cohort. The incidence of PG in the pediatric heart failure population is also high with a reported range of 21-37% (9)(10)(11)27). Unlike the adult literature where pre-transplant cachexia is a strong predictor of mortality, the pediatric literature has described varying effects (6).…”

Section: Discussionmentioning

confidence: 99%

Hypoalbuminemia and poor growth predict worse outcomes in pediatric heart transplant recipients

Castleberry

White‐Williams

Naftel

et al. 2014

Pediatric Transplantation

View full text Add to dashboard Cite

Children with end-stage cardiac failure are at risk of HA and PG. The effects of these factors on post-transplant outcome are not well defined. Using the PHTS database, albumin and growth data from pediatric heart transplant patients from 12/1999 to 12/2009 were analyzed for effect on mortality. Covariables were examined to determine whether HA and PG were risk factors for mortality at listing and transplant. HA patients had higher waitlist mortality (15.81% vs. 10.59%, p = 0.015) with an OR of 1.59 (95% CI 1.09-2.30). Survival was worse for patients with HA at listing and transplant (p ≤ 0.01 and p = 0.026). Infants and patients with congenital heart disease did worse if they were HA at time of transplant (p = 0.020 and p = 0.028). Growth was poor while waiting with PG as risk factor for mortality in multivariate analysis (p = 0.008). HA and PG are risk factors for mortality. Survival was worse in infants and patients with congenital heart disease. PG was a risk factor for mortality in multivariate analysis. These results suggest that an opportunity may exist to improve outcomes for these patients by employing strategies to mitigate these risk factors.

show abstract

“…The lack of normative data in the younger pediatric age impedes clinical research in this area. Although an individual patient can use as his/her own serial DEXA bone density measurements to gauge bone mineral content, the age‐related changes secondary to growth makes interpretation more difficult (25–27). Patients found to suffer bone mineral loss will benefit from dietary plus calcium supplementation to achieve minimal calcium intakes of 1500 mg/day.…”

Section: Recommendationsmentioning

confidence: 99%

Post‐transplant metabolic bone complications and optimization of treatment

Chan¹

2007

Pediatric Transplantation

View full text Add to dashboard Cite

Growth after pediatric heart transplantation

Cited by 9 publications

References 7 publications

Anthropometric growth and utilization of enteral feeding support in pediatric heart transplant recipients

Anthropometric growth and utilization of enteral feeding support in pediatric heart transplant recipients

Hypoalbuminemia and poor growth predict worse outcomes in pediatric heart transplant recipients

Post‐transplant metabolic bone complications and optimization of treatment

Contact Info

Product

Resources

About